WideCells Group PLC (LON:WDC) has announced its one-year anniversary to the London Stock Exchange.
The Group was established in order to transform the stem cell industry by creating the first end-to-end service solutions to make stem cell treatment accessible and affordable globally in a market projected to be worth US$170 billion by 2020. Since our listing on 27 July 2016 the Company has made formidable progress in creating a dynamic, revenue generative business.
Over the last year Widecells have seen their three divisions grow at an impressive rate.
- CellPlan, a unique insurance product offering customers an end-to-end service to manage the full treatment process, is now being launched on a global scale and is generating revenues in the UK.
- WideAcademy is being spearheaded by ex-Apple Director Alan Greenberg, who will ensure it as the thought leader on stem cell technologies and innovation for medical professionals and families. This division will not only be self-funded but also profitable.
- WideCells, the research division of the Group, is now licenced by the HTA and will see innovative projects come into fruition in the near term.
Widecells Group also became a licenced provider of INDUS, a novel synthetic bone graft which promotes new bone formation. The Group intends to start selling this product within the UK in the coming months, initially targeting the dental industry, with potential for further roll out internationally.
Such developments are reflected in the Company’s ranking in the DISRUPT 100 list, which viewed WideCells as the 21st most disruptive company globally. This index celebrates the potential to influence, change or create new global markets, something which is at the forefront of Widecell’s vision.
Furthermore, WideCells has been shortlisted for ‘UK Life Science IPO of the Year’ at this year’s 2017 Biotech and Money Awards due to take place at Merchant Taylors Hall in London in September. Widecells Group will be attending and networking at the ceremony this year.
Widecells Group CEO, João Andrade said: Reflecting on the past year, I am extremely proud of how much we have achieved and thankful to the whole WideCells team who have helped us to get to where we are today. However, this is just the beginning of what is yet to come, from raising £2m to create and develop the achievements that currently surround us, to signing deals with cord blood banks across the world and securing contracts to undertake pioneering stem cell research and ultimately build our presence across the globe, we look forward to scaling up on our service reach and building revenues.
I would also like to thank all of our shareholders for their dedication and in making these achievements possible.
